Abpro/Celltrion ABP-102/CT-P72 preclinical data at AACR 2025 shows potential best-in-class HER2 x CD3 T-cell engager

Abpro Holdings, Inc.

ABP-102/CT-P72 preclinical data presented orally at AACR 2025; co-developed with Celltrion via strategic partnership.
Up to 2-fold increase in tumor suppression vs. runimotamab biosimilar in HER2-overexpressing cancer models.
Reduced cytokine release and tolerated >180x the MTD of parental antibody in monkeys, suggesting wider therapeutic window.
Phase 1 clinical trials planned to commence in first half of 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.